Sirolimus associated pneumonitis in a hematopoietic stem cell transplant patient

[1]  Shi‐Chuan Chang,et al.  Unusual radiological presentation of sirolimus-associated pneumonitis. , 2013, Journal of the Chinese Medical Association : JCMA.

[2]  A. Lupo,et al.  Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors , 2013, Clinical & developmental immunology.

[3]  P. Małkowski,et al.  Early everolimus-induced pneumonitis in a renal transplant recipient: A case report. , 2012, Annals of transplantation.

[4]  A. Palazzo,et al.  Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials , 2012, Acta oncologica.

[5]  K. Cornetta,et al.  Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  G. Pond,et al.  Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. , 2006, European journal of cancer.

[7]  L. Bubendorf,et al.  Patterns of Pulmonary Complications Associated with Sirolimus , 2006, Respiration.

[8]  S. Lachance,et al.  Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.